PDGFRB and dermatofibrosarcoma protuberans: Therefore, some researchers believe that sunitinib may have good efficacy in treating DFSP patients who fail imatinib mesylate treatment, possibly related to the fact that sunitinib’s binding ability with PDGFRB is ten times that of imatinib mesylate [28, 29].